Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHO-H01 as a Single Agent/Combined With Lenalidomide to Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
NCT05950165Phase 2Active, not recruiting
- Sponsor
- CHO Pharma
- Start
- Jan 2020
- Primary completion
- Dec 2026
- Modality
- Naked Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cho-h01 in non-Hodgkin lymphoma (NHL), sponsored by CHO Pharma. Started Jan 2020; status: active, not recruiting.
02
Drugs
cho-h01
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05950165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05950165.